Agriculture
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Research Report 2025
- May 05, 25
- ID: 228014
- Pages: 92
- Figures: 95
- Views: 7
The global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at US$ 409 million in the year 2024 and is projected to reach a revised size of US$ 669 million by 2031, growing at a CAGR of 7.4% during the forecast period.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
North American market for Inactivated Vaccine for Swine Mycoplasma Pneumonia is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Inactivated Vaccine for Swine Mycoplasma Pneumonia is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Santé Animale, Harbin Pharmaceutical Group, Pulike Biotech, Qilu Animal Health Products, Wuhan Keqian Biology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine for Swine Mycoplasma Pneumonia.
The Inactivated Vaccine for Swine Mycoplasma Pneumonia market size, estimations, and forecasts are provided in terms of output/shipments (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santé Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
by Type
Single Vaccine
Dual Vaccine
by Application
Piglets
Adult Pigs
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Inactivated Vaccine for Swine Mycoplasma Pneumonia by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Inactivated Vaccine for Swine Mycoplasma Pneumonia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
North American market for Inactivated Vaccine for Swine Mycoplasma Pneumonia is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Inactivated Vaccine for Swine Mycoplasma Pneumonia is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Santé Animale, Harbin Pharmaceutical Group, Pulike Biotech, Qilu Animal Health Products, Wuhan Keqian Biology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine for Swine Mycoplasma Pneumonia.
The Inactivated Vaccine for Swine Mycoplasma Pneumonia market size, estimations, and forecasts are provided in terms of output/shipments (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santé Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
by Type
Single Vaccine
Dual Vaccine
by Application
Piglets
Adult Pigs
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Inactivated Vaccine for Swine Mycoplasma Pneumonia by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Inactivated Vaccine for Swine Mycoplasma Pneumonia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.
1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Overview
1.1 Product Definition
1.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type
1.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Growth Rate Analysis by Type: 2024 VS 2031
1.2.2 Single Vaccine
1.2.3 Dual Vaccine
1.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application
1.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Growth Rate Analysis by Application: 2024 VS 2031
1.3.2 Piglets
1.3.3 Adult Pigs
1.4 Global Market Growth Prospects
1.4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
1.4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity Estimates and Forecasts (2020-2031)
1.4.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Estimates and Forecasts (2020-2031)
1.4.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price Estimates and Forecasts (2020-2031)
1.5 Assumptions and Limitations
2 Market Competition by Manufacturers
2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Manufacturers (2020-2025)
2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Manufacturers (2020-2025)
2.3 Global Key Players of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Industry Ranking, 2023 VS 2024
2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (2020-2025)
2.6 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Product Offered and Application
2.8 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Date of Enter into This Industry
2.9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Situation and Trends
2.9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate
2.9.2 Global 5 and 10 Largest Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Market Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region (2020-2031)
3.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region (2020-2025)
3.2.2 Global Forecasted Production Value of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region (2026-2031)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Volume by Region (2020-2031)
3.4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region (2020-2025)
3.4.2 Global Forecasted Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region (2026-2031)
3.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Price Analysis by Region (2020-2025)
3.6 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production and Value, Year-over-Year Growth
3.6.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.3 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.4 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region
4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2031)
4.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025)
4.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption by Region (2026-2031)
4.3 North America
4.3.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.3.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.3.3 U.S.
4.3.4 Canada
4.4 Europe
4.4.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.4.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031
4.5.2 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2031)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.6.2 Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2020-2031)
5.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2020-2025)
5.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2026-2031)
5.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2020-2031)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2020-2031)
5.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2020-2025)
5.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2026-2031)
5.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2020-2031)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2020-2031)
6 Segment by Application
6.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2020-2031)
6.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2020-2025)
6.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2026-2031)
6.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2020-2031)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2020-2031)
6.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2020-2025)
6.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2026-2031)
6.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2020-2031)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2020-2031)
7 Key Companies Profiled
7.1 Zoetis
7.1.1 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.1.2 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.1.4 Zoetis Main Business and Markets Served
7.1.5 Zoetis Recent Developments/Updates
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.2.2 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.2.4 Boehringer Ingelheim Main Business and Markets Served
7.2.5 Boehringer Ingelheim Recent Developments/Updates
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.3.2 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.3.4 Jinhe Biotechnology Main Business and Markets Served
7.3.5 Jinhe Biotechnology Recent Developments/Updates
7.4 Merck
7.4.1 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.4.2 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.4.4 Merck Main Business and Markets Served
7.4.5 Merck Recent Developments/Updates
7.5 HIPRA
7.5.1 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.5.2 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.5.4 HIPRA Main Business and Markets Served
7.5.5 HIPRA Recent Developments/Updates
7.6 Ceva Santé Animale
7.6.1 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.6.2 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.6.3 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.6.4 Ceva Santé Animale Main Business and Markets Served
7.6.5 Ceva Santé Animale Recent Developments/Updates
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.7.2 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.7.4 Harbin Pharmaceutical Group Main Business and Markets Served
7.7.5 Harbin Pharmaceutical Group Recent Developments/Updates
7.8 Pulike Biotech
7.8.1 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.8.2 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.8.4 Pulike Biotech Main Business and Markets Served
7.8.5 Pulike Biotech Recent Developments/Updates
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.9.2 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.9.4 Qilu Animal Health Products Main Business and Markets Served
7.9.5 Qilu Animal Health Products Recent Developments/Updates
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.10.2 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.10.4 Wuhan Keqian Biology Main Business and Markets Served
7.10.5 Wuhan Keqian Biology Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
8.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Material Supply Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Mode & Process Analysis
8.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Marketing
8.4.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Channels
8.4.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors
8.5 Inactivated Vaccine for Swine Mycoplasma Pneumonia Customer Analysis
9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Dynamics
9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Trends
9.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
9.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
9.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
10 Research Findings and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 Market Size Estimation
11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer
1.1 Product Definition
1.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type
1.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Growth Rate Analysis by Type: 2024 VS 2031
1.2.2 Single Vaccine
1.2.3 Dual Vaccine
1.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application
1.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Growth Rate Analysis by Application: 2024 VS 2031
1.3.2 Piglets
1.3.3 Adult Pigs
1.4 Global Market Growth Prospects
1.4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
1.4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity Estimates and Forecasts (2020-2031)
1.4.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Estimates and Forecasts (2020-2031)
1.4.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price Estimates and Forecasts (2020-2031)
1.5 Assumptions and Limitations
2 Market Competition by Manufacturers
2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Manufacturers (2020-2025)
2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Manufacturers (2020-2025)
2.3 Global Key Players of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Industry Ranking, 2023 VS 2024
2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (2020-2025)
2.6 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Product Offered and Application
2.8 Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Date of Enter into This Industry
2.9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Situation and Trends
2.9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate
2.9.2 Global 5 and 10 Largest Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Market Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region (2020-2031)
3.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region (2020-2025)
3.2.2 Global Forecasted Production Value of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region (2026-2031)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Volume by Region (2020-2031)
3.4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region (2020-2025)
3.4.2 Global Forecasted Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region (2026-2031)
3.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Price Analysis by Region (2020-2025)
3.6 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production and Value, Year-over-Year Growth
3.6.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.3 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
3.6.4 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Estimates and Forecasts (2020-2031)
4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region
4.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2031)
4.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025)
4.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption by Region (2026-2031)
4.3 North America
4.3.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.3.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.3.3 U.S.
4.3.4 Canada
4.4 Europe
4.4.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.4.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031
4.5.2 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2031)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.6.2 Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2031)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2020-2031)
5.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2020-2025)
5.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Type (2026-2031)
5.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2020-2031)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2020-2031)
5.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2020-2025)
5.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Type (2026-2031)
5.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2020-2031)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2020-2031)
6 Segment by Application
6.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2020-2031)
6.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2020-2025)
6.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Application (2026-2031)
6.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2020-2031)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2020-2031)
6.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2020-2025)
6.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Application (2026-2031)
6.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2020-2031)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2020-2031)
7 Key Companies Profiled
7.1 Zoetis
7.1.1 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.1.2 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.1.4 Zoetis Main Business and Markets Served
7.1.5 Zoetis Recent Developments/Updates
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.2.2 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.2.4 Boehringer Ingelheim Main Business and Markets Served
7.2.5 Boehringer Ingelheim Recent Developments/Updates
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.3.2 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.3.4 Jinhe Biotechnology Main Business and Markets Served
7.3.5 Jinhe Biotechnology Recent Developments/Updates
7.4 Merck
7.4.1 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.4.2 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.4.4 Merck Main Business and Markets Served
7.4.5 Merck Recent Developments/Updates
7.5 HIPRA
7.5.1 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.5.2 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.5.4 HIPRA Main Business and Markets Served
7.5.5 HIPRA Recent Developments/Updates
7.6 Ceva Santé Animale
7.6.1 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.6.2 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.6.3 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.6.4 Ceva Santé Animale Main Business and Markets Served
7.6.5 Ceva Santé Animale Recent Developments/Updates
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.7.2 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.7.4 Harbin Pharmaceutical Group Main Business and Markets Served
7.7.5 Harbin Pharmaceutical Group Recent Developments/Updates
7.8 Pulike Biotech
7.8.1 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.8.2 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.8.4 Pulike Biotech Main Business and Markets Served
7.8.5 Pulike Biotech Recent Developments/Updates
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.9.2 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.9.4 Qilu Animal Health Products Main Business and Markets Served
7.9.5 Qilu Animal Health Products Recent Developments/Updates
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
7.10.2 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Portfolio
7.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Value, Price and Gross Margin (2020-2025)
7.10.4 Wuhan Keqian Biology Main Business and Markets Served
7.10.5 Wuhan Keqian Biology Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
8.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Material Supply Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Mode & Process Analysis
8.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Marketing
8.4.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Channels
8.4.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors
8.5 Inactivated Vaccine for Swine Mycoplasma Pneumonia Customer Analysis
9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Dynamics
9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Trends
9.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
9.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
9.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
10 Research Findings and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 Market Size Estimation
11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer
List of Tables
Table 1. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Type, (US$ Million) & (2024 VS 2031)
Table 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Application, (US$ Million) & (2024 VS 2031)
Table 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units) by Manufacturers in 2024
Table 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Manufacturers (2020-2025) & (K Units)
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Manufacturers (2020-2025)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Manufacturers (2020-2025) & (US$ Million)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Share by Manufacturers (2020-2025)
Table 8. Global Key Players of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Industry Ranking, 2023 VS 2024
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2024)
Table 10. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (US$/Unit) & (2020-2025)
Table 11. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Manufacturing Base Distribution and Headquarters
Table 12. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Product Offered and Application
Table 13. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Date of Enter into This Industry
Table 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Region (2020-2025)
Table 18. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Region (2020-2025)
Table 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Forecast by Region (2026-2031)
Table 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share Forecast by Region (2026-2031)
Table 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Comparison by Region: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Region (2020-2025)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Region (2020-2025)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) Forecast by Region (2026-2031)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share Forecast by Region (2026-2031)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price (US$/Unit) by Region (2020-2025)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price (US$/Unit) by Region (2026-2031)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031 (K Units)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025) & (K Units)
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region (2020-2025)
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption by Region (2026-2031) & (K Units)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption Market Share by Region (2026-2031)
Table 33. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 34. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 35. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 36. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 37. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 38. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 39. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031 (K Units)
Table 40. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025) & (K Units)
Table 41. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2026-2031) & (K Units)
Table 42. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 43. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 44. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 45. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Type (2020-2025)
Table 46. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Type (2026-2031)
Table 47. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2020-2025)
Table 48. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2026-2031)
Table 49. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Type (2020-2025)
Table 50. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Type (2026-2031)
Table 51. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2020-2025)
Table 52. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2026-2031)
Table 53. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2020-2025)
Table 54. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2026-2031)
Table 55. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Application (2020-2025)
Table 56. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Application (2026-2031)
Table 57. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2020-2025)
Table 58. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2026-2031)
Table 59. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Application (2020-2025)
Table 60. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Application (2026-2031)
Table 61. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2020-2025)
Table 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2026-2031)
Table 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2020-2025)
Table 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2026-2031)
Table 65. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 66. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 67. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 68. Zoetis Main Business and Markets Served
Table 69. Zoetis Recent Developments/Updates
Table 70. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 71. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 72. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Main Business and Markets Served
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 76. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 77. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Jinhe Biotechnology Main Business and Markets Served
Table 79. Jinhe Biotechnology Recent Developments/Updates
Table 80. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 81. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 82. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck Main Business and Markets Served
Table 84. Merck Recent Developments/Updates
Table 85. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 86. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 87. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. HIPRA Main Business and Markets Served
Table 89. HIPRA Recent Developments/Updates
Table 90. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 91. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 92. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ceva Santé Animale Main Business and Markets Served
Table 94. Ceva Santé Animale Recent Developments/Updates
Table 95. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 96. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 97. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Harbin Pharmaceutical Group Main Business and Markets Served
Table 99. Harbin Pharmaceutical Group Recent Developments/Updates
Table 100. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 101. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 102. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Pulike Biotech Main Business and Markets Served
Table 104. Pulike Biotech Recent Developments/Updates
Table 105. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 106. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 107. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Qilu Animal Health Products Main Business and Markets Served
Table 109. Qilu Animal Health Products Recent Developments/Updates
Table 110. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 111. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 112. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Wuhan Keqian Biology Main Business and Markets Served
Table 114. Wuhan Keqian Biology Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors List
Table 118. Inactivated Vaccine for Swine Mycoplasma Pneumonia Customers List
Table 119. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Table 120. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
Table 121. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 122. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Type, (US$ Million) & (2020-2031)
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Type: 2024 VS 2031
Figure 4. Single Vaccine Product Picture
Figure 5. Dual Vaccine Product Picture
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Application, (US$ Million) & (2020-2031)
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application: 2024 VS 2031
Figure 8. Piglets
Figure 9. Adult Pigs
Figure 10. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) & (2020-2031)
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units) & (2020-2031)
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) & (2020-2031)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (US$/Unit) & (2020-2031)
Figure 15. Inactivated Vaccine for Swine Mycoplasma Pneumonia Report Years Considered
Figure 16. Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Share by Manufacturers in 2024
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Share by Manufacturers (2024)
Figure 18. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 19. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2024
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Region: 2020 VS 2024 VS 2031
Figure 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Comparison by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Region: 2020 VS 2024 VS 2031
Figure 24. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 25. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 26. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 27. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region: 2020 VS 2024 VS 2031
Figure 30. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 31. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 32. U.S. Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 33. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 34. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 35. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 36. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 37. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 38. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 39. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 40. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 41. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 42. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region (2020-2031)
Figure 43. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 44. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 45. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 46. China Taiwan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 47. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 48. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 49. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 50. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 51. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 52. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 53. Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 54. GCC Countries Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 55. Global Production Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2020-2031)
Figure 56. Global Production Value Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2020-2031)
Figure 57. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Production Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application (2020-2031)
Figure 59. Global Production Value Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application (2020-2031)
Figure 60. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2020-2031)
Figure 61. Inactivated Vaccine for Swine Mycoplasma Pneumonia Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Table 1. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Type, (US$ Million) & (2024 VS 2031)
Table 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Application, (US$ Million) & (2024 VS 2031)
Table 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units) by Manufacturers in 2024
Table 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Manufacturers (2020-2025) & (K Units)
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Manufacturers (2020-2025)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Manufacturers (2020-2025) & (US$ Million)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Share by Manufacturers (2020-2025)
Table 8. Global Key Players of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Industry Ranking, 2023 VS 2024
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2024)
Table 10. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (US$/Unit) & (2020-2025)
Table 11. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Manufacturing Base Distribution and Headquarters
Table 12. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Product Offered and Application
Table 13. Global Key Manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia, Date of Enter into This Industry
Table 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Region (2020-2025)
Table 18. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Region (2020-2025)
Table 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Forecast by Region (2026-2031)
Table 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share Forecast by Region (2026-2031)
Table 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Comparison by Region: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Region (2020-2025)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Region (2020-2025)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) Forecast by Region (2026-2031)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share Forecast by Region (2026-2031)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price (US$/Unit) by Region (2020-2025)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Average Price (US$/Unit) by Region (2026-2031)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031 (K Units)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025) & (K Units)
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region (2020-2025)
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption by Region (2026-2031) & (K Units)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Forecasted Consumption Market Share by Region (2026-2031)
Table 33. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 34. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 35. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 36. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 37. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 38. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 39. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Region: 2020 VS 2024 VS 2031 (K Units)
Table 40. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2020-2025) & (K Units)
Table 41. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region (2026-2031) & (K Units)
Table 42. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units)
Table 43. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2020-2025) & (K Units)
Table 44. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Country (2026-2031) & (K Units)
Table 45. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Type (2020-2025)
Table 46. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Type (2026-2031)
Table 47. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2020-2025)
Table 48. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Type (2026-2031)
Table 49. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Type (2020-2025)
Table 50. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Type (2026-2031)
Table 51. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2020-2025)
Table 52. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Type (2026-2031)
Table 53. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2020-2025)
Table 54. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2026-2031)
Table 55. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Application (2020-2025)
Table 56. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) by Application (2026-2031)
Table 57. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2020-2025)
Table 58. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Application (2026-2031)
Table 59. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Application (2020-2025)
Table 60. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) by Application (2026-2031)
Table 61. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2020-2025)
Table 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Application (2026-2031)
Table 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2020-2025)
Table 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2026-2031)
Table 65. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 66. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 67. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 68. Zoetis Main Business and Markets Served
Table 69. Zoetis Recent Developments/Updates
Table 70. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 71. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 72. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Main Business and Markets Served
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 76. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 77. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Jinhe Biotechnology Main Business and Markets Served
Table 79. Jinhe Biotechnology Recent Developments/Updates
Table 80. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 81. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 82. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck Main Business and Markets Served
Table 84. Merck Recent Developments/Updates
Table 85. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 86. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 87. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. HIPRA Main Business and Markets Served
Table 89. HIPRA Recent Developments/Updates
Table 90. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 91. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 92. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ceva Santé Animale Main Business and Markets Served
Table 94. Ceva Santé Animale Recent Developments/Updates
Table 95. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 96. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 97. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Harbin Pharmaceutical Group Main Business and Markets Served
Table 99. Harbin Pharmaceutical Group Recent Developments/Updates
Table 100. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 101. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 102. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Pulike Biotech Main Business and Markets Served
Table 104. Pulike Biotech Recent Developments/Updates
Table 105. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 106. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 107. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Qilu Animal Health Products Main Business and Markets Served
Table 109. Qilu Animal Health Products Recent Developments/Updates
Table 110. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Company Information
Table 111. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Specification and Application
Table 112. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Wuhan Keqian Biology Main Business and Markets Served
Table 114. Wuhan Keqian Biology Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors List
Table 118. Inactivated Vaccine for Swine Mycoplasma Pneumonia Customers List
Table 119. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Table 120. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers
Table 121. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 122. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Type, (US$ Million) & (2020-2031)
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Type: 2024 VS 2031
Figure 4. Single Vaccine Product Picture
Figure 5. Dual Vaccine Product Picture
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value by Application, (US$ Million) & (2020-2031)
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application: 2024 VS 2031
Figure 8. Piglets
Figure 9. Adult Pigs
Figure 10. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) & (2020-2031)
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units) & (2020-2031)
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K Units) & (2020-2031)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (US$/Unit) & (2020-2031)
Figure 15. Inactivated Vaccine for Swine Mycoplasma Pneumonia Report Years Considered
Figure 16. Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Share by Manufacturers in 2024
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Share by Manufacturers (2024)
Figure 18. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 19. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2024
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value Market Share by Region: 2020 VS 2024 VS 2031
Figure 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Comparison by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Region: 2020 VS 2024 VS 2031
Figure 24. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 25. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 26. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 27. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Value (US$ Million) Growth Rate (2020-2031)
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region: 2020 VS 2024 VS 2031
Figure 30. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 31. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 32. U.S. Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 33. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 34. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 35. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 36. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 37. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 38. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 39. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 40. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 41. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 42. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Region (2020-2031)
Figure 43. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 44. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 45. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 46. China Taiwan Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 47. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 48. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 49. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 50. Latin America, Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Market Share by Country (2020-2031)
Figure 51. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 52. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 53. Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 54. GCC Countries Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption and Growth Rate (2020-2031) & (K Units)
Figure 55. Global Production Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2020-2031)
Figure 56. Global Production Value Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2020-2031)
Figure 57. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Production Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application (2020-2031)
Figure 59. Global Production Value Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Application (2020-2031)
Figure 60. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit) by Application (2020-2031)
Figure 61. Inactivated Vaccine for Swine Mycoplasma Pneumonia Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232